Evaluating cognitive impairment in the clinical setting: practical screening and assessment tools

Area of Science:

• Neuroscience
• Infectious Diseases
• Virology

Background:

• HIV-associated neurocognitive disorders (HAND) remain a significant clinical challenge despite advances in combination antiretroviral therapy.
• Existing screening tools like the Mini Mental State Exam and HIV Dementia Scale lack sufficient sensitivity for early HAND detection.
• The Montreal Cognitive Assessment shows potential but may require adjunctive testing to enhance clinical sensitivity.

Observation:

• Patient self-reporting of HAND symptoms is often unreliable, as many individuals with HAND are asymptomatic.
• Cerebrospinal fluid (CSF) analysis for HIV RNA is indicated in specific cases to detect viral load.
• CSF viral escape (detectable HIV RNA in CSF but not plasma) is infrequent in clinical practice.

Findings:

• Cognitive improvements in cases of CSF escape correlate with antiretroviral regimen modifications targeting resistance or enhancing central nervous system (CNS) penetration.
• Current evidence is insufficient to recommend routine intensification of antiretroviral therapy for most HAND patients without specific indicators.
• Expert opinions vary regarding optimal treatment strategies, highlighting ongoing uncertainty in managing HAND.

Implications:

• Improved diagnostic methods are crucial for sensitive and timely HAND identification in clinical settings.
• Understanding CSF viral dynamics and CNS penetration-effectiveness is key for optimizing treatment in HAND.
• Further research and consensus are needed to establish standardized, evidence-based treatment guidelines for HAND management.